CD47 as a promising therapeutic target in oncology
CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipu...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.757480/full |
| _version_ | 1818496777846784000 |
|---|---|
| author | Hai Zhao Shuangshuang Song Junwei Ma Zhiyong Yan Hongwei Xie Ying Feng Shusheng Che |
| author_facet | Hai Zhao Shuangshuang Song Junwei Ma Zhiyong Yan Hongwei Xie Ying Feng Shusheng Che |
| author_sort | Hai Zhao |
| collection | DOAJ |
| description | CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipulates synaptic pruning during neuronal development. As such, CD47 has recently be regarded as one of novel innate checkpoint receptor targets for cancer immunotherapy. In this review, we will discuss increasing awareness about the diverse functions of CD47 and its role in immune system homeostasis. Then, we will discuss its potential therapeutic roles against cancer and outlines, the possible future research directions of CD47- based therapeutics against cancer. |
| first_indexed | 2024-12-10T18:37:14Z |
| format | Article |
| id | doaj.art-37072b3a1bb5499ab0d2584e5645c3db |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-10T18:37:14Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-37072b3a1bb5499ab0d2584e5645c3db2022-12-22T01:37:47ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-08-011310.3389/fimmu.2022.757480757480CD47 as a promising therapeutic target in oncologyHai Zhao0Shuangshuang Song1Junwei Ma2Zhiyong Yan3Hongwei Xie4Ying Feng5Shusheng Che6Department of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, ChinaDepartment of Nuclear Medicine, the Affiliated Hospital of Qingdao University, Qingdao, ChinaDepartment of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, ChinaDepartment of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, ChinaDepartment of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, ChinaDepartment of Emergency, the Affiliated Hospital of Qingdao University, Qingdao, ChinaDepartment of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, ChinaCD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipulates synaptic pruning during neuronal development. As such, CD47 has recently be regarded as one of novel innate checkpoint receptor targets for cancer immunotherapy. In this review, we will discuss increasing awareness about the diverse functions of CD47 and its role in immune system homeostasis. Then, we will discuss its potential therapeutic roles against cancer and outlines, the possible future research directions of CD47- based therapeutics against cancer.https://www.frontiersin.org/articles/10.3389/fimmu.2022.757480/fullCD47SIRPαimmune modulationimmunotherapiescancer immunotherapyatherosclerosis |
| spellingShingle | Hai Zhao Shuangshuang Song Junwei Ma Zhiyong Yan Hongwei Xie Ying Feng Shusheng Che CD47 as a promising therapeutic target in oncology Frontiers in Immunology CD47 SIRPα immune modulation immunotherapies cancer immunotherapy atherosclerosis |
| title | CD47 as a promising therapeutic target in oncology |
| title_full | CD47 as a promising therapeutic target in oncology |
| title_fullStr | CD47 as a promising therapeutic target in oncology |
| title_full_unstemmed | CD47 as a promising therapeutic target in oncology |
| title_short | CD47 as a promising therapeutic target in oncology |
| title_sort | cd47 as a promising therapeutic target in oncology |
| topic | CD47 SIRPα immune modulation immunotherapies cancer immunotherapy atherosclerosis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.757480/full |
| work_keys_str_mv | AT haizhao cd47asapromisingtherapeutictargetinoncology AT shuangshuangsong cd47asapromisingtherapeutictargetinoncology AT junweima cd47asapromisingtherapeutictargetinoncology AT zhiyongyan cd47asapromisingtherapeutictargetinoncology AT hongweixie cd47asapromisingtherapeutictargetinoncology AT yingfeng cd47asapromisingtherapeutictargetinoncology AT shushengche cd47asapromisingtherapeutictargetinoncology |